how does repatha cause diabetes

Repatha, used for managing hypercholesterolemia, has been associated with a potential risk of diabetes. This risk is primarily linked to the drug's mechanism of action and the patient's health profile.

Repatha functions by inhibiting a protein known as PCSK9, which enhances the liver's ability to clear low-density lipoprotein (LDL) cholesterol, thus lowering circulating levels of 'bad' cholesterol. However, this process might also impact insulin secretion and sensitivity, given that PCSK9 is present not only in the liver but also in pancreatic beta cells, which are crucial for insulin production. Inhibition of PCSK9 could disrupt insulin's normal release, affecting glucose regulation and potentially increasing the risk of diabetes.

Patient variability is another significant factor. Genetic predisposition, age, and body weight may influence individual responses to Repatha, heightening the risk of diabetes. For instance, obese patients might experience increased insulin resistance due to the higher resistance of their adipose tissue to insulin, which could be exacerbated by Repatha use, further elevating the risk of diabetes.

For patients on Repatha, vigilant monitoring of blood glucose levels and regular testing are essential. Should any diabetes symptoms emerge, such as polydipsia, polyuria, or weight loss, they should seek immediate medical attention and disclose their Repatha use to their healthcare provider. Additionally, adhering to a healthy lifestyle, including a balanced diet and regular physical activity, can help mitigate the risk of diabetes.